- £30.13bn
- £38.66bn
- £11.30bn
- 83
- 34
- 88
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.72 | ||
| PEG Ratio (f) | 1.1 | ||
| EPS Growth (f) | 19.29% | ||
| Dividend Yield (f) | 1.98% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.81 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 17.08 | ||
| Price to Sales | 2.68 | ||
| EV to EBITDA | 17.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.88% | ||
| Return on Equity | 6.58% | ||
| Operating Margin | 18.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 8,480 | 9,892 | 9,545 | 10,858 | 11,302 | 11,454.84 | 11,947.27 | 7.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +33.79 | +13.84 | -11.32 | -18.52 | +25.83 | +9.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 20th, 2021
- Public Since
- July 18th, 2022
- No. of Shareholders
- 61,447
- No. of Employees
- 24,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 9,132,301,104
- Address
- Building 5, First Floor, The Heights, WEYBRIDGE, KT13 0NY
- Web
- https://www.haleon.com/
- Phone
- +44 1932822000
- Contact
- Sonya Ghobrial
- Auditors
- KPMG LLP
Latest News for HLN
Upcoming Events for HLN
HALEON PLC Annual Shareholders Meeting
Half Year 2024 HALEON PLC Earnings Release
Q3 2024 HALEON PLC Trading Statement Release
Similar to HLN
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
Argent BioPharma
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 19:10 UTC, shares in HALEON are trading at 329.90p. This share price information is delayed by 15 minutes.
Shares in HALEON last closed at 329.90p and the price had moved by -2.18% over the past 365 days. In terms of relative price strength the HALEON share price has underperformed the FTSE All Share Index by -7.14% over the past year.
The overall consensus recommendation for HALEON is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The HALEON dividend yield is 1.82% based on the trailing twelve month period.
Last year, HALEON paid a total dividend of £0.06, and it currently has a trailing dividend yield of 1.82%.Looking ahead, the next dividend pay date is 2024-05-16.
We do not have data on when HALEON is to next pay dividends. The historic dividend yield on HALEON shares is currently 1.82%.
To buy shares in HALEON you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 329.90p, shares in HALEON had a market capitalisation of £30.13bn.
Here are the trading details for HALEON:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HLN
Based on an overall assessment of its quality, value and momentum HALEON is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in HALEON is 366.00p. That is 10.94% above the last closing price of 329.90p.
Analysts covering HALEON currently have a consensus Earnings Per Share (EPS) forecast of £0.18 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HALEON. Over the past six months, its share price has underperformed the FTSE All Share Index by -7.36%.
As of the last closing price of 329.90p, shares in HALEON were trading +0.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HALEON PE ratio based on its reported earnings over the past 12 months is 17.72. The shares last closed at 329.90p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on HALEON's directors